Glow Blend 70mg + NAD+ 500mg Research Bundle
USA Made, ≥99% Purity Per Compound
4.9 177 verified reviews- Separate retail vials: Glow Blend 70mg (GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg); NAD+ 500mg
- USA manufactured in a Certified GMP California and Arizona laboratory.
- ≥99% purity target per compound with third-party HPLC, mass spectrometry, and batch-specific COAs
For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.
Per-compound specifications
2 vialsNothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.
- CAS
- GHK-Cu: 89030-95-5; BPC-157: 137525-51-0; TB-500: 885340-08-9
- Molecular mass
- GHK-Cu: 402.92; BPC-157: 1,419.5; TB-500: 889.01 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- CAS
- 53-84-9
- Molecular mass
- 663.43 g/mol (anhydrous free-acid basis)
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- Form
- 2 Separate Lyophilized Powders
- Purity target
- ≥99% per compound (3rd-Party HPLC Tested)
- Origin
- All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
- Storage
- Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light
What is the Glow Blend and NAD+ Research Bundle?
This two-vial bundle pairs Glow Blend 70mg with NAD+ 500mg. Glow contains GHK-Cu 50mg, BPC-157 10mg, and TB-500 10mg in one formulated vial; NAD+ is a separate non-peptide coenzyme used in redox and enzyme-signaling research.
The grouping supports controlled study of copper coordination, extracellular-matrix, vascular, cytoskeletal, and cellular energy pathways. Each retail product keeps its original formulation, and no combined clinical effect is implied.
How It Works
GHK-Cu supports copper and matrix research: Models examine copper coordination, fibroblast activity, gene expression, and extracellular-matrix remodeling.
BPC-157 and TB-500 add distinct cellular signals: Research examines vascular and migration pathways plus an actin-binding cytoskeletal motif.
NAD+ supports redox and enzyme research: It carries electrons and supplies substrate for sirtuins, PARPs, CD38, and related enzymes.
One certificate per vial
Independent third-party HPLC assesses each compound against its ≥99% purity target, while mass spectrometry confirms identity. For each vial, the results are documented in one combined, batch-specific COA report.
- Lot
- GL-49504
- Reported
- 2026-05-06
- Identity (LC-MS)
- Confirmed
- Purity (HPLC-UV)
- 99.46%
- Net content
- 70.49 mg
- Appearance
- White lyophilized powder
- Lot
- NA-75688
- Reported
- 2026-05-12
- Identity (LC-MS)
- Confirmed
- Purity (HPLC-UV)
- 99.64%
- Net content
- 502.00 mg
- Appearance
- White lyophilized powder
Why Source from 321 Peptides?
Lot history 8 released lots
Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.
| Compound | Lot | Reported | Purity | Net content | COA |
|---|---|---|---|---|---|
| Glow Blend 70mg | GL342 | 2026-06-01 | 99.76% | GHK-Cu - 56.40 mg, BPC-157 - 10.26 mg, Thymosin Beta-4 - 10.74 mg | |
| GL-49504 | 2026-05-06 | 99.46% | 70.49 mg | Pending | |
| GL-50081 | 2026-05-02 | 99.58% | 70.56 mg | Pending | |
| GL-48927 | 2026-04-08 | 99.49% | 70.42 mg | Pending | |
| NAD+ 500mg | NA430 | 2026-06-01 | 99.83% | 535.51 mg | |
| NA-75688 | 2026-05-12 | 99.64% | 502.00 mg | Pending | |
| NA-76265 | 2026-04-30 | 99.88% | 502.50 mg | Pending | |
| NA-76842 | 2026-02-25 | 99.71% | 503.00 mg | Pending |